rabbit polyclonal anti-caveolin 3  (Thermo Fisher)

Journal: Experimental and Therapeutic Medicine

Article Title: Effect of type 2 diabetes mellitus caveolin-3 K15N mutation on glycometabolism

doi: 10.3892/etm.2019.7840

Figure Lengend Snippet: K15N mutation effect on protein expression in the AKT signaling pathway. Western blot and densitometry analysis of (A) CAV3-eGFP, (B) CAV1, (C) p-AKT, (D) AKT1 and AKT2, (E) GLUT-4 and (F) p-GSK3β expression in WT and K15N cells. All data are presented as the mean ± standard deviation. *P<0.05 vs. WT. CAV3, caveolin-3; eGFP, enhanced green fluorescent protein; CAV-1, caveolin-1; p, phosphorylated; GLUT-4, glucose transporter type 4; GSK3β, glycogen synthase kinase 3β; WT, wild-type; K15N, CAV3 K15N mutation.

Article Snippet: Membranes were blocked with 5% dried skim milk and TBS plus 0.01% Tween 20 for 1 h at room temperature and subsequently incubated overnight at 4°C with mouse anti-GFP monoclonal antibody (1:500; cat. no. J20625; Beijing Transgen Biotech Co., Ltd.), mouse anti-CAV3 monoclonal antibody (1:100; cat. no. sc-5310; Santa Cruz Biotechnology, Inc.), rabbit anti-caveolin-1 (CAV1) polyclonal antibody (1:1,000; cat. no. sc-894; Santa Cruz Biotechnology, Inc.), mouse anti-phosphorylated (p)-AKT ser473 monoclonal antibody (1:1,000; cat. no. 12694; Cell Signaling Technology, Inc.), mouse anti-AKT monoclonal antibody (1:1,000; cat. no. 2920; Cell Signaling Technology, Inc.), goat anti-AKT1 polyclonal antibody (1:1,000; cat. no. sc-1618; Santa Cruz Biotechnology, Inc.), mouse anti-AKT2 monoclonal antibody (1:1,000; cat. no. 5239; Cell Signaling Technology, Inc.), goat anti-GLUT-4 polyclonal antibody (1:100; cat. no. sc-01608; Santa Cruz Biotechnology, Inc.), rabbit anti-p glycogen synthase kinase 3 beta (GSK3β) monoclonal antibody (1:1,000; cat. no. 9323; Cell Signaling Technology, Inc.) or rabbit anti-GSK3β monoclonal antibody (1:1,000; cat. no. 9315; Cell Signaling Technology, Inc.).

Techniques: Mutagenesis, Expressing, Western Blot, Standard Deviation